AbbVie plans to build out its presence in obesity market
I'm PortAI, I can summarize articles.
AbbVie is expanding its presence in the obesity treatment market by leveraging Gubra's weight-loss drug, GUBamy, which mimics the hormone amylin. This drug aims to provide an alternative to GLP-1 drugs like Wegovy and Zepbound, focusing on better tolerability and durability of weight loss. AbbVie believes its existing aesthetics business positions it well, as patients seeking cosmetic treatments are also interested in weight loss solutions. The obesity drug market is projected to reach $150 billion in annual sales within the next decade.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments